Spelling suggestions: "subject:"transforming erowth 3factor"" "subject:"transforming erowth 4factor""
1 |
The solution structure and surface properties of TB3 of LTBP-1Lack, Jeremy David January 2001 (has links)
No description available.
|
2 |
Development of macrophage cytosensors capable of detecting programming signals within models of glomerular inflammationBrooksbank, Katriona J. M. January 2002 (has links)
We have developed a novel TGF-β detection system, using genetically modified macrophages as cytokine biosensors, capable of detecting bioactive TGF-β in vivo and in vitro. Stimulation by TGF-β1 increases secretion of plasminogen activator inhibitor-1 (PAI-1) by activation of the promoter. An adenovirus containing the first 800bp of the PAI-1 promoter fused to the reporter gene β-galactosidase (Ad-PAI1800 βgal) was used to transfect primary cultures of rat bone marrow derived macrophages (BMDM). After transfection the BMDM were stimulated with TGF-β, 2 or 3 or left unstimulated. X-gal histochemical assay was performed 72-hours post-transfection to detect β-galactosidase expression. Macrophages transfected with Ad-PAI1800βgal and stimulated with TGF-β1, 2 or 3 showed a dose-dependent production of β-galacosidase. AdPAI1800βgal BMDM also expressed β-galactosidase when co-cultured with NR8383 rat alveolar macrophages transfected with recombinant adenovirus expressing active TGF-β1. Genetically modified macrophages could detect expression of TGF-β1 in vivo. AdPAI1800βgal transfected BMDM were co-injected with AdTGF-βl transfected NR8383 macrophages into the renal artery of rats with nephrotoxic nephritis (NTN). Isolated glomeruli showed X-gal positive macrophages on assay. AdPAI1800βgal BMDM were also injected into the renal artery of rats 7 days after the induction of Thy 1.1 nephritis, 100% of isolated glomeruli contained X-gal positive macrophages on assay. Signalling macrophages were capable of detecting TGF-β1 expression in sections of kidney tissue containing Ad-TGF-β1 transfected NR8383 macrophages. BMDM showing β-galactosidase were readily detected over the transfected glomeruli. Pre-treatment of Ad-PAI1800βgal transfected BMDM with IFN-γ prevented production of the reporter gene. However when stimulation with TGF-β occurred 20 hours after IFN-γ macrophage programmed unresponsiveness was abrogated. Macrophage responsiveness to TGF-β stimulation in Thy 1.1 nephritic kidneys was also prevented by pre-treatment with IFN-γ. This system demonstrates the use of genetically modified macrophages as both <i>in vivo </i>and <i>in vitro </i>sensors of the bioactive TGF-β providing a novel approach to assess cytokine activity.
|
3 |
Analyse der Auswirkungen von TGF-beta auf den Cadherin-Catenin-Adhäsionskomplex in den epithelialen Karzinomzelllinien SW-480 und MCF-7Nguyen-tat, Marc-Daniel, January 2006 (has links)
Ulm, Univ. Diss., 2006.
|
4 |
Pre-existing intimal hyperplasia and overexpression of TGF-ß1 in saphenous vein grafts before myocardial revascularization in humans: implications for aortocoronary saphenous vein graft diseaseLi, Jun, January 2001 (has links)
Ulm, Univ., Diss., 2001.
|
5 |
Binding properties and solution structure of the TGF-[beta] type I receptor extracellular domain : a dissertation /Zuniga, Jorge E. January 2007 (has links)
Dissertation (Ph.D.).--University of Texas Graduate School of Biomedical Sciences at San Antonio, 2007. / Vita. Includes bibliographical references.
|
6 |
Molekulare Mechanismen der Antiöstrogenwirkung beim MammakarzinomBuck, Miriam. January 2002 (has links)
Stuttgart, Univ., Diss., 2002.
|
7 |
Roles for TGF-β in Pulmonary Disease / TGF-β1 in FibrosisGalt, Thomas January 2001 (has links)
Fibrosis is a disease where the normally transitory wound healing response enters a chronic state. Bleomycin and Adenovector models of pulmonary fibrosis have implicated TGF-β1 in this disease. Concern regarding a synergistic combination of TGF-β1 with an adaptive immune response within the Adenovector model prompted its use within mice devoid of T Lymphocytes, Balb/c SCIDs. The lack of an adaptive immune response within these mice did not affect the severity of fibrogenesis, as compared to Balb/c data in a hydroxyproline assay. TGF-β1 is a pluripotent cytokine with key roles in wound healing, immune regulation, and development, making it a dangerous molecule to therapeutically modulate directly. Future strategies will likely focus on downstream fibrotic molecules uninvolved in immune regulation, such as CTGF. While CTGF has been associated with fibrosis and is likely activated by TGF-β1, no conclusive evidence is available within an animal model. TGF-β1 stimulates cells by binding its receptor and signaling through the Smad signal transduction pathway. Smad3 knockout mice were used to examine the regulation of CTGF by TGF-β1, and study its role in pulmonary fibrosis. We show that these mice produce dramatically less CTGF in response to TGF-β1 than littermates expressing Smad3, and they show protection against TGF-β1 induced pulmonary fibrosis, using the Adenovector system. TGF-β1 can alter lung development, and is thought to be a causative agent in Bronchopulmonary Dysplasia, a disease affecting immature lungs. Utilizing the Adenovector system, we developed a neonatal rat model of BPD that closely resembles the human disease, providing researchers with a system to study the disease course. TGF-β1 is part of a family of growth factors, of which TGF-β3 is also a member. What role TGF-β3 plays in pulmonary fibrosis has not been evaluated. To allow future in vivo studies on the effect of TGF-β3 on lung morphology, we constructed a replication deficient Adenovector expressing constitutively active TGF-β3. / Thesis / Master of Science (MSc)
|
8 |
Biologische Charakterisierung der Rezeptoren für Transforming Growth Faktor-ß / Biological charakterization of the receptors for Transforming Growth Factor-ßRotzer, Diana January 2001 (has links) (PDF)
Transforming growth factor-ß (TGF-ß) reguliert eine Vielzahl zellulärer Funktionen, wie Proliferation, Differenzierung und Apoptose. Über membrangebundene Serin/Threonin-Kinase-Rezeptoren werden TGF-ß Signale durch Phosphorylierung an Smad-Proteine, die intrazellulären Signaltransduktoren, weitergeleitet, die im Kern die Transkription spezifischer Gene modulieren. Obwohl die drei TGF-ß Isoformen, TGF-ß1, -ß2 und -ß3, äußerst homologe Proteine sind, unterscheiden sich die Phänotypen ihrer Genknockouts stark. Variabilität und Spezifität können auf vielerlei Arten und Ebenen der TGF-ß Signalübertragung erreicht werden. In der vorliegenden Arbeit wird eine alternativ gespleißte Variante des TGF-ß Typ II Rezeptors (TßRII), TßRII-B, charakterisiert. Dieser Rezeptor ist, im Gegensatz zum bisher bekannten TßRII, in der Lage alle drei TGF-ß Isoformen hochaffin zu binden und in Abwesenheit eines unterstützenden Typ III Rezeptors (TßRIII) Signale über den Smad-Pathway weiterzuleiten. TßRII-B ist außerdem fähig ligandenabhängig mit den verschiedenen TGF-ß Rezeptortypen zu Oligomerisieren. Erste Hinweise auf Besonderheiten der TGF-ß2 Bindung an TßRII-B wurden mittels verschiedener zellbiologischer Ansätzen gewonnen. Aus Untersuchungen zur gewebespezifischen Expression des Rezeptors geht hervor, daß TßRII-B, im Vergleich zu TßRII, ein distinktes Expressionsmuster aufweist und v.a. in TGF-ß2-beeinflußten Geweben nachgewiesen werden kann. In diesen Erkenntnissen spiegelt sich die Bedeutung dieses Rezeptors für eine TGF-ß Isoform-spezifische Signalübertragung wider. Der zweite Teil der vorliegenden Arbeit beschäftigt sich mit der Rolle von TGF-ß und seinen Rezeptoren bei der Entstehung von Tumoren. B-Zellen einiger Patienten mit chronischer lymphatischer Leukämie (B-CLL), der häufigsten Form adulter Leukämie in westlichen Ländern, zeigen Resistenz gegenüber TGF-ß-vermittelter Wachstumsinhibierung und ein verändertes Expressionsmuster der TGF-ß Rezeptoren an ihrer Zelloberfläche. In dieser Arbeit wird die Identifizierung und Charakterisierung zweier Mutationen innerhalb der putativen Signalpeptidsequenz des TGF-ß Typ I Rezeptors (TßRI) in B-Zellen TGF-ß resistenter CLL-Patienten beschrieben. Hierbei handelt es sich um einen Aminosäure-Austausch (L12Q) und eine ‚in-frame‘ Alanin-Deletion (A8) innerhalb einer aus 9 Alaninen bestehenden Sequenz. Es konnte gezeigt werden, daß diese Mutationen zwar keinen Einfluß auf Oberflächenexpression und Komplexbildungseigenschaften des TßRI haben, jedoch TGF-ß stimulierte Reportergeninduktion verringern, was eine kausale Beziehung bei der Entwicklung TGF-ß resistenter B-CLL-Zellen vermuten läßt. Ein Auftreten von Mutationen innerhalb der 9-Alanin-Sequenz des TßRI korreliert mit TGF-ß Insensitivität von B-CLL Zellen. Obwohl noch weitere Studien benötigt werden, um den präzisen molekularen Mechanismus zu verstehen, der zu TGF-ß Resistenz in B-CLL Zellen führt, kann spekuliert werden, daß TßRI Mutationen das Voranschreiten von B-CLL und evtl. anderen Tumorarten unterstützen. Gezieltes Screenen nach TßRI Signalpeptidsequenz Mutationen könnte demnach als prognostischer Indikator für Tumorprogression eingesetzt werden. / Transforming growth factor-ß (TGF-ß) regulates a variety of cellular functions like proliferation, differentiation and apoptosis. It signals through membrane-bound serine/threonine kinase receptors, which upon stimulation phosphorylate Smad proteins, the intracellular signaltransducers, and thereby trigger their nuclear translocation and transcriptional activity. Although the three mammalian TGF-ß isoforms, TGF-ß1, -ß2 and –ß3, are highly homologous proteins, the phenotypes of their genknockouts reveal striking differences. Variability and specificity can be achieved on different levels of the TGF-ß signaltransduction. In this work an alternatively spliced variant of the TGF-ß type II receptor (TßRII), TßRII-B, is characterized, which in contrast to TßRII binds and mediates signaling of all TGF-ß isoforms. This signaling occurs via the Smad pathway and is independent of any supporting type III receptor (TßRIII). Therefore interaction and oligomerization of TßRII-B with the TGF-ß isoforms as well as the different TGF-ß receptor types was analyzed in detail. Furthermore we defined the characteristics of TGF-ß2 binding to TßRII-B. Expression studies demonstrate that TßRII-B expression is restricted to cells originating from tissues where the TGF-ß2 isoform has a predominant role. All that reflects the importance of this receptor splice-variant in TGF-ß isoform-specific signaling. The second part of this work focuses on the role of TGF-ß and its receptors in tumor development. B cell chronic lymphocytic leukemia (B-CLL) is the most common lymphoid cancer in Western societies, and is also currently incurable. B-cells from some B-CLL patients are resistant to the growth inhibitory effects of TGF-ß and show a different expression pattern of TGF-ß receptors at their cell surface. In this work the identification and characterization of two mutations within the putative signal sequence of the tßrI gene in B-cells from TGF-ß resistant B-CLL patients is described. Thereby a single aminoacid substitution (L12Q) is accompanied by an ‘in frame’ single alanine deletion within an 9-alanine stretch. It could be shown that this mutations do not mediate the apparent loss of functional TßRI in TGF-ß resistant B-CLL, but they attenuate reporter gene induction stimulated by TGF-ß, suggesting a causal relationship in the development of TGF-ß resistant B-CLL. The appearance of mutations within the 9-alanine stretch of the TßRI correlated with and predicted for B-CLL patient insensitivity to TGF-ß. Although more studies are needed to ascertain the precise molecular mechanism leading to TGF-ß resistance in B-CLL cells, it is tempting to speculate that these TßRI mutations may promote the progression of B-CLL and other cancers from their indolent to active states. This suggests that screening for TßRI signal sequence mutations can be employed as a prognostic indicator of B-CLL patient sensitivity to TGF-ß.
|
9 |
Klonierung, Expression und Charakterisierung von Mutanten des Bone Morphogenetic Protein-2 / Cloning, expression and characterization of mutant bone morphogenetic protein-2Vogel, Friederike January 2002 (has links) (PDF)
Das Zytokin Bone Morphogenetic Protein-2 (BMP-2) gehört als Mitglied der Transforming Growth Factor ß-Superfamilie zu einer großen Gruppe eng verwandter Wachstums- und Differenzierungsfaktoren. Es spielt eine entscheidende Rolle bei Bildung und Regeneration von Knorpel und Knochen und während verschiedener Prozesse der embryonalen Entwicklung. Durch Sezernierung des Proteins und anschließende Diffusion in der extrazellulären Matrix (EZM) ausgehend vom Ort der Sekretion unterliegt sein Wirkungsgrad einem abnehmenden Konzentrationsgradienten. BMP-2 bindet neben der hochaffinen Bindung an seinen spezifischen Rezeptor unter anderem auch an die extrazelluläre Matrix. So konnte in Vorarbeiten bereits durch Deletion der basischen Heparinbindungsstelle des BMP-2, die sich im N-terminalen Bereich befindet, eine Wirkungsverstärkung des Proteins in einem in vitro- Experiment, dem Hühnergliedmaßentest, erreicht werden, da die konkurrierende Bindung an Heparinbindungsstellen der EZM wegfällt. Im Tiermodell konnte jedoch ein genau umgekehrter Effekt dieser Mutante im Vergleich mit dem Wildtyp gezeigt werden, da in vivo die Diffusion des Moleküls durch Bindung an die EZM begrenzt und es so lokal an seinem Wirkungsort konzentriert wird. Von diesen Vorbefunden ausgehend war das Ziel der Arbeit die Klonierung und Expression von Mutanten des BMP-2, bei denen durch schrittweise Modifizierung der Heparinbindungsstelle die Bindung des Proteins an Heparin und deren Einfluß auf die Rezeptorbindung charakterisiert werden sollte. Dazu wurden zwei Mutanten des BMP-2 mit Verdopplung eines bzw. beider basischer Aminosäuretripletts kloniert, da diesem basischen Bereich im N-Terminus die eigentliche Bindung an Heparin zugeschrieben wird. Nach Expression, Renaturierung und säulenchromatographischer Aufreinigung der Proteine konnte in dieser Arbeit in drei verschiedenen funktionellen in vitro-Tests eine abnehmende Wirkung der Mutanten gezeigt werden. Neben dem biophysikalischen Nachweis der apparenten Affinitäten der Mutanten zu Rezeptor und Matrix in Biacore-Messungen konnte die Änderung des Wirkungsgrades auch in einem Zellkulturassay mit einer Maus-Fibroblasten-Zellinie durch Messung der Alkalischen Phosphatase und im Hühnergliedmaßentest gezeigt werden. In in vivo Experimenten bleibt eine entsprechende zu erwartende Wirkungsverstärkung dieser beiden Mutanten nachzuweisen, die im Hinblick auf einen therapeutischen Einsatz bei gewünschtem Ersatz zerstörten Knochens relevant werden könnte. / Bone morphogenetic protein-2 is a cytokine belonging to the TGFß-superfamily. We performed a modification of its heparin binding site in order to investigate a possible correlation between the basic acids of the heparin binding site and the function of the protein in vitro.
|
10 |
Studies of bladder cancer progressionHung, Tzong Tyng, Clinical School - Prince of Wales Hospital, Faculty of Medicine, UNSW January 2009 (has links)
Bladder cancer (BlCa) is the second most common genitourinary cancer, affecting both men and women. Most (70%) cases present at the superficial stage; 20% of these recur with muscle-invasive disease. Major genetic alterations associated with BlCa include: loss/gain in expression or mutations in Retinoblastoma (RB) gene, human epidermal growth factor receptors (HERs), H-ras, p53 and FGFR3. Only p53 mutations are well correlated with invasive BlCa; other changes show variable correlations with disease status. To understand the progression of BlCa, a model of nine human BlCa cell sublines derived from a single parent but differing in in vivo characteristics, has been developed previously. These cells represent a heterogenous population from a single tumour and a model of different stages of BlCa progression, from non-tumourigenic to invasive. Two sublines were selected for further investigation: C3 (non-tumourigenic) and B8 (invasive). These were transfected with green (C3-GSP-2) and red fluorescent reporters (B8-RSP-gck) respectively to investigate the effects of their co-injection in vivo, specifically, promotion of C3 tumour growth by B8 cells. Surprisingly, B8 tumour growth was inhibited by C3 cells in vivo at different cell numbers and proportions of cells injected. Microarray analysis of C3 and B8 cells revealed differential expression of 1367 genes with dramatic differences in the transforming growth factor-?? and integrin-mediated pathways. Gene expression of BMP2, INHBB, FST, NOG, ID4 and TGF- ??1, in the TGF- ?? pathway was further analysed with qRT-PCR in all nine sublines. Expression of BMP2 was significantly related to tumourigenic potential (p=0.0238, Mann-Whitney) and INHBB to invasive ability (p=0.0476, Mann-Whitney). The BlCa model did not include a metastatic component. To broaden the model, cell lines were established from an invaded lymph-node (B8-RSP-LN) and a bone-metastasis (B8-RSP-BN) after subcutaneous and intra-cardiac injection of B8-RSP-gck cells. No significant differences were observed in the migratory capability and anchorage-independent colony formation of these metastatic cells compared with B8 cells. Evaluation of expression of the panel of TGF-beta genes (BMP2, INHBB, FST, NOG, ID4 and TGF- ??1) and metastasis-related genes (MMP9, MMP2 and KAI1) indicated that expression of BMP2, FST, ID4 and MMP9 was decreased or lost in the metastatic sublines.
|
Page generated in 0.0994 seconds